peptide drug conjugate fda approved FDA approved 68 Ga PSMA-11 - Research advances inpeptide drugconjugates peptide-drug conjugate

Research advances inpeptide drugconjugates

FDA-Approved Peptide Drug Conjugates: A Growing Frontier in Targeted Therapy

The landscape of targeted therapeutics has been significantly advanced by the development of peptide drug conjugates (PDCs), a class of drugs designed to deliver potent payloads directly to specific cells.Peptide-drug conjugates: A new paradigm for targeted ... The FDA-approved peptide drug conjugate landscape is rapidly evolving, offering new hope for treating various diseases, most notably cancer.作者：C Fu·2022·被引用次数：187—The first PDC approved by the US Food and Drug Administration (FDA),177Lu-dotatate, is used to treat gastrointestinal, pancreatic, and neuroendocrine tumors49... These sophisticated molecules combine the targeting precision of peptides with the efficacy of cytotoxic drugs, minimizing systemic toxicity and maximizing therapeutic impact.2024年6月6日—In December 2020, theFDA approved 68 Ga PSMA-11as the first diagnostic reagent indicated for PET in men with PSMA-positive lesions. The drug ...

Currently, the number of FDA-approved PDCs is relatively small but growing, with key examples paving the way for future innovations.2024年4月30日—FDA Approved PDCs. Currently, there are only two PDCs approved for therapeutic use globally.177Lu-DOTA-TATE (Lutathera®) is the world's first ... Understanding these approved agents is crucial for appreciating the potential and current status of this therapeutic modality.

#### Key FDA-Approved Peptide Drug Conjugates

The journey of FDA-approved PDCs has seen the emergence of several critical agents, primarily in the realm of oncology作者：W Xiao·2025·被引用次数：186—Table 2Peptide-based drug approved by FDA from 2014 to 2024. Full size table. Table 3 Peptide-based drug in clinical phase III. Full size ....

* Lutathera (177Lu-dotatate or 177Lu-DOTA-TATE): This radiolabeled peptide is a landmark therapy. Approved by the FDA, Lutathera targets somatostatin receptors, which are often overexpressed on neuroendocrine tumorsPeptide–drug conjugates (PDCs): a novel trend of ... - PMC - NIH. The attached radioactive isotope, Lutetium-177, delivers targeted radiation directly to cancer cells expressing these receptors, making it a crucial treatment for certain gastrointestinal and pancreatic neuroendocrine tumors.Advance in peptide-based drug development: delivery ... Novartis developed this pioneering drug, which was among the first PDCs to receive FDA approvalFDA Approved Antibody-Drug Conjugates (ADCs) By 2026.

* Pepaxto (Melflufen): Another significant FDA-approved PDC is Pepaxto, also known as melflufen.2025年6月5日—As of May 2025,2 peptide drug conjugates have been approvedby the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment ... This drug is a peptide-drug conjugate designed to target cancer cells. It was approved for specific hematological malignancies, demonstrating the versatility of PDCs beyond solid tumors. However, it's important to note that regulatory statuses can evolve, and some approvals, like that for Pepaxto in certain contexts, have seen complexities or withdrawals in different regions, underscoring the dynamic nature of drug approval.

* 68Ga PSMA-11: While primarily a diagnostic reagent for PET imaging in men with prostate cancer, 68Ga PSMA-11 represents an important FDA-approved peptide conjugate. Its approval highlights the utility of peptide conjugates not only for therapy but also for precise disease detection, which is a critical component of personalized cancer care.The United States Food andDrugAdministration (FDA) hasapproveda plethora ofpeptide-baseddrugsas effectivedrugsin cancer therapy.

It is worth noting that there can be variations in how PDCs are categorized, and some sources may list different numbers or types of approvals depending on the specific criteria used (e.g., including diagnostic agents, or distinguishing between therapeutic and diagnostic radiopharmaceuticals). However, Lutathera and Pepaxto are consistently cited as key therapeutic PDCs.

#### The Mechanism and Promise of Peptide Drug Conjugates

Peptide drug conjugates operate on a principle of targeted delivery.Peptide-Drug Conjugates and Their Targets in Advanced ... A peptide, which is a short chain of amino acids, is carefully selected for its ability to bind to specific receptors or antigens that are highly expressed on the surface of diseased cells, such as cancer cells.2024年4月30日—FDA Approved PDCs. Currently, there are only two PDCs approved for therapeutic use globally.177Lu-DOTA-TATE (Lutathera®) is the world's first ... This peptide acts as a homing deviceCurrently, the market hastwo FDA-approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, the rising prevalence .... Attached to the peptide, via a linker molecule, is a potent therapeutic payloadPeptide Drug Conjugates: A New Frontier in Targeted .... This payload is often a cytotoxic drug, capable of killing cells, or in the case of radiolabeled PDCs, a radioactive isotope that induces cell death through radiation.

When the PDC encounters a cell expressing the target receptor, the peptide binds to it, facilitating the internalization of the entire conjugate into the cell.2025年7月11日—Although theFDAhas withdrawn approval for Pepaxto, the EMA and the UK's MHRA haveapprovedit under the brand name Pepaxti for use in ... Once inside, the linker is cleaved, releasing the cytotoxic payload or activating the radioactive isotope. This localized release ensures that the toxic effects are concentrated within the targeted cells, thereby sparing healthy tissues and reducing the debilitating side effects often associated with conventional chemotherapy.

The advantage of using peptides over larger molecules like antibodies (as in Antibody-Drug Conjugates or ADCs) lies in their smaller sizeFDA Approved Antibody-Drug Conjugates (ADCs) By 2026. This allows PDCs to potentially penetrate solid tumors more effectively and be cleared from circulation more rapidly, which can be beneficial for drug delivery and reducing off-target toxicities.

#### Future Directions and Research Advances

The success of currently approved peptide drug conjugates has spurred significant research and development efforts. Scientists are exploring novel peptides that can target a wider range of cancers and other diseases, as well as developing more sophisticated linker technologies and potent payloads. The field is also looking at combining PDCs with other therapeutic modalities, such as immunotherapy, to achieve synergistic effects.Currently, two PDC drugs (Figure 1) are approved for marketing by the U.S. Food and Drug Administration (FDA).177Lu-DOTA-TATE (Lutathera) was approved in 2018 ...

The development of PDCs represents a significant step forward in precision medicine. As our understanding of disease biology deepens and our capabilities in molecular engineering advance, we can anticipate an expanding pipeline of FDA-approved peptide drug conjugates, offering more effective and less toxic treatment options for patients facing serious illnesses. The journey from research bench to FDA approval is complex, but the growing list of approved agents signifies a promising future for this innovative class of therapeutics.